Expert Consensus on the Clinical Application of Oral Small-molecule Antiviral Drugs Against COVID-19  

作　　者：无 Nanshan Zhong Guiqiang Wang 

机构地区：[1]Society of Bacterial Infection and Resistance of Chinese Medical Association [2]National Clinical Research Center for Respiratory Disease,National Center for Respiratory Medicine [3]First Affiliated Hospital of Guangzhou Medical University,Guangzhou Institute of Respiratory Health,National Clinical Research Center for Respiratory Disease,National Center for Respiratory Medicine,State Key Laboratory of Respiratory Disease,Guangzhou 510120,China [4]Department of Infectious Diseases,Peking University First Hospital,Beijing 100034,China

出　　处：《Infectious Diseases & Immunity》2024年第4期158-169,共12页感染性疾病与免疫（英文）

基　　金：Emergency Key Program of Guangzhou Laboratory(EKPG21-06);the Macao Science and Technology Development Fund(0022/2021/A1);the Young Top Talent of Science and Technology Innovation Department of Guangdong Province(2021TQ060189);National Administration of Traditional Chinese Medicine’s Interdisciplinary Innovation Team Project(ZYYCXTU-D-202201).

摘　　要：Although COVID‑19 no longer constitutes a“public health emergency of international concern”,which still has being spreading around the world at a low level.Small molecule drugs are the main antiviral treatment for novel coronavirus recommended in China.Although a variety of small‑molecule antiviral drugs against COVID‑19 have been listed in China,there is no specific drug recommendation for special populations.Society of Bacterial Infection and Resistance of Chinese Medical Association,together with the National Clinical Research Center for Respiratory Disease,and the National Center for Respiratory Medicine,organized domestic experts in various fields such as respiratory,virology,infection,critical care,emergency medicine and pharmacy to release Expert Consensus on the Clinical Application of Oral Small‑Molecule Antiviral Drugs against COVID‑19.The main content of this consensus includes the introduction of seven small‑molecule antiviral drugs against COVID‑19,focusing on the drug recommendations for 14 special groups such as the elderly,patients with complicated chronic diseases,tumor patients,pregnant women,and children,and providing suggestions for clinicians to standardize drug use.

关 键 词：Coronavirus infections Antiviral therapy Small molecule drugs Early stage Expert consensus 

分 类 号：R563.1[医药卫生—呼吸系统]